As known, I share your sentiment regarding Veneto. But, let’s give the benefit of the doubt in one key valuation area. The lowered negotiated price is around $14 million less, or nearly equal the amount ($15 mil) of the first tranche payment, which was for the pharmacies and lab. Obviously, we then need to hope the MSO is a worthwhile acquisition. DME-IQ seemed super early stage with just that one customer, so I wouldn’t factor that in as worth anything until it’s proven. But, perhaps the MSO model kept physicians and it wasn’t a wind down of pharmacies that still was the majority of those far lower than projected (by Generex) revenues.